DM Clinical Research Earns 2023 Best Clinical Trial Network Award
DM Clinical Research was named the 2023 Best Clinical Trial Network at the annual Vaccine Industry Excellence (ViE) Awards held during the World Vaccine Congress Washington, the leading global vaccine congress.
“We are incredibly honored by this award from the clinical research community as it recognizes our success in helping research partners develop safe and effective vaccines to improve lives,” said DM Clinical Research CEO & Founder Mohammad Millwala. “The honor is a tribute to the dedication of our employees, to the absolute highest quality research, and the patients who volunteer for clinical trials to help provide the world with life-saving vaccines and medications. We are thankful to our research partners for their continuing commitment and trust in partnering with DM Clinical Research to help advance medicine.”
The 2023 Best Clinical Trial Network Award comes during a period of transformational growth for DM Clinical Research, an integrated national network of wholly owned clinical trial sites headquartered in Houston, with sites in Boston, Chicago, Detroit, and Philadelphia, and more on the way this year. Over the last three years, the company’s staff size has quadrupled from 87 to 541 and its dedicated research sites have increased from seven to 13. The vaccine industry honor also builds on the company’s achievements in the last year, which included being named the 2022 Society for Clinical Research Sites (SCRS) Excellence in Patient Centricity Award.
“DM Clinical Research expects this growth and success to continue for the foreseeable future,” said Millwala. “The company has earned a reputation as an extremely dependable and transparent site network focused on quality, safety, and robust diverse enrollment for all of our research partners. These are just a few of the many reasons for our continued success.”
